$1.40
-0.03 (-2.10%)
Open$1.42
Previous Close$1.43
Day High$1.43
Day Low$1.40
52W High$1.96
52W Low$1.17
Volume—
Avg Volume19.5K
Market Cap68.42M
P/E Ratio—
EPS$-0.19
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+1,935.7% upside
Current
$1.40
$1.40
Target
$28.50
$28.50
$17.57
$28.50 avg
$41.49
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 405.6K | 11.04M | 11.56M |
| Net Income | -11,948,632 | -536,425 | -578,623 |
| Profit Margin | -2,928.8% | -4.9% | -5.0% |
| EBITDA | -13,224,131 | -810,707 | -735,622 |
| Free Cash Flow | — | -370,627 | -351,629 |
| Rev Growth | — | +9.7% | -0.5% |
| Debt/Equity | — | 0.96 | 0.89 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |